Last reviewed · How we verify
Vaxigrip®: Split virion inactivated influenza vaccine
At a glance
| Generic name | Vaxigrip®: Split virion inactivated influenza vaccine |
|---|---|
| Also known as | Vaxigrip® |
| Sponsor | Sanofi Pasteur, a Sanofi Company |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Safety and Immunogenicity of the Butantan Institute Influenza Vaccine Compared to Sanofi Pasteur Influenza Vaccine (PHASE4)
- Study of Sanofi Pasteur's Intradermal Influenza Vaccine (IDflu™) in Adults and Elderly in Korea (PHASE4)
- A Time-motion Study Comparing Self- to Nurse-vaccination With Influenza Vaccine (PHASE4)
- Study of Immune Response in Adults and Elderly Subjects Vaccinated With Inactivated Influenza Vaccines (PHASE2)
- Study of Inactivated, Split-Virion Influenza Vaccine Compared With the Reference Vaccine Vaxigrip® in the Elderly (PHASE3)
- Immunogenicity of the Inactivated Split-Virion Influenza Vaccine in Renal Transplant Subjects (PHASE2)
- Immunogenicity Study of the Influenza Vaccine in Adults (PHASE2)
- Study of Inactivated, Split-Virion Influenza Vaccine Administered by Intradermal Route Versus Vaxigrip® in Adults (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |